barre

Learn How to Pull Off the Cage Braid You Love From Instagram

Cage-Braid-How-

All Images: Courtesy of POPSUGAR Beauty/Benjamin Stone

popsugarblack_small.jpg

Like most of the epic braids we envy, we first spotted the cage braid on Instagram. The plait is a combination of the classic french and a fishtail. A central braid sits between little waterfalls of hair that move from the outside in. The finished plait looks just like a ribcage. At first glance, it seems impossible to do at home, but it is a lot easier to achieve than it looks (we promise!). T3 celebrity hairstylist David Lopez broke down the twisted style into three simple steps ahead.

Makeup by Maya Calhoun of Stylisted.

Step 1: Section Off Hair

Step-1-Section-Off-Hair

Make a middle part and divide hair into three sections: two from hairline to crown and one large back section. Start a french braid at the very top of the crown section.

Step 2: Weave In Hair

Step-2-Weave-Hair

This is where the braid takes the form of a fishtail. As you continue down the hair, you want to add in small pieces of hair from the two front sections. Just like in the classic fishtail braid, you want to grab hair from the outermost section over, but leave it loose.

The Braid

Braid

Once you’ve added all the hair in, the braid looks like a medieval version of the french braid.

Step 3: Pin Up

Step-3-Pin-Up

To reveal the “cage,” lift the braid at the crown and insert a bobby pin. This creates separation between the central plait and the hair underneath, giving the style a 3D ribcage effect.

The Finished Cage Braid

Finished-Cage-Braid

The Finished Look

Finished-Look

More from Popsugar Beauty:

21 Sheet Masks That Will Solve Your Every Skin Care Woe

10 Pumpkin Beauty Products That Will Make You Pumped For Fall

You’ll Love the Way This DIY Pumpkin Scrub Smells and Feels

This May Be the Chicest Holiday Beauty Collection We’ve Seen Yet!

popsugarblack_small.jpg POPSUGAR Beauty puts the focus on hair, makeup, nails, and fragrance — from inspiring celebrity photos and fun polls, to easy how-tos to re-create the latest trends at home, to expert tips from the world’s top stylists! Find out the latest color trends for your face, hair, and nails with hot new products and daring nail design ideas. DIY ideas turn your home into a spa, and make you knowledgeable on any beauty topic. Let POPSUGAR Beauty be your guide to all things skin care, makeup, and hair care!



from Health News / Tips & Trends / Celebrity Health http://ift.tt/1MiRhSD

In Rare Cases, Hepatitis C Drug Tied to Slowed Heart Rate: Study

By Dennis Thompson
HealthDay Reporter

WEDNESDAY, Nov. 4, 2015 (HealthDay News) — One of the new, highly effective drugs for treating hepatitis C can cause a very slow and erratic heart rate in some patients, new research warns.

Doctors at a Paris hospital found that three out of 415 chronic hepatitis C patients treated with the drug sofosbuvir during 2014 developed an abnormally slow heart rate, called an bradyarrhythmia.

In all three cases, the patients were also receiving other hepatitis C medications, including daclatasvir, simeprevir and ribavirin, according to the report.

“The potential cardiac toxicity of sofosbuvir-containing regimens suggests the need for caution with the use of such regimens,” the Parisian doctors concluded in the report. They suggested that doctors review other medications and potential risk factors for an abnormal heart rate before prescribing the drug. And, they pointed out the possible need to monitor the heart rate when starting treatment with sofosbuvir.

The study findings were published in the Nov. 5 issue of the New England Journal of Medicine.

Sofosbuvir is approved for use in the United States. But, in March 2015, the U.S. Food and Drug Administration warned that a person’s heart rate can become seriously slowed when hepatitis C drug regimens, including sofosbuvir plus another antiviral drug, are used with a heart rhythm medication called amiodarone, background information in the study said.

The FDA warning included the drugs Harvoni and Sovaldi, both of which contain sofosbuvir.

Sofosbuvir has been a breakthrough treatment for people with chronic hepatitis C, the authors said. Treatment with the drug causes viral levels to drop and remain low in more than 90 percent of patients, and the rate of serious adverse events is less than 5 percent, the study authors said.

However, these problems are cropping up because sofosbuvir is being used in a wider group of patients with widely varying degrees of health, said Dr. David Bernstein, chief of hepatology for the North Shore-LIJ Health System in New Hyde Park, N.Y.

“They’re being used in more and more patients because they’re felt to be extremely safe, but some of the patients now being treated would never have been allowed into any of the clinical trials,” Bernstein said.

Bernstein noted that clinical trials involved about 2,000 people, but now hundreds of thousands of patients are taking sofosbuvir. “Now we’re going to see the greater experience, and what the larger risks are,” he said.

People need to be aware of this potential side effect, but Bernstein said he still considers sofosbuvir a safe drug. He added that he hopes that hepatitis C patients won’t decline the drug over fears of heart trouble.

“It’s just important that people don’t overreact to this,” Bernstein said.

Dr. Andrew Muir, an associate professor and clinical director of hepatology at Duke University Medical Center, agreed that these heart concerns are probably limited to a small number of patients. He also felt these findings shouldn’t deter hepatitis C patients from taking the drug.

“This whole class of agents have transformed treatment for hepatitis C, and many more patients have been cured,” Muir said.

Physicians prescribing sofosbuvir need to check the other drugs their patients are taking, and be mindful of potential heart effects, Muir said. Liver disease specialists might even consider consulting with heart doctors, he suggested.

“This reminds us all that when you are treating patients with other health issues, we need to be mindful of that,” he said. “Such patients should be treated by someone with significant experience in hepatitis C, and their physician should be ready to consult with other specialists.”

More information

For more about hepatitis C, visit the American Liver Foundation.





from Health News / Tips & Trends / Celebrity Health http://ift.tt/1MAJ7Rl

Tapeworm May Have Spread Cancer Cells to Colombian Man

By Amy Norton
HealthDay Reporter

WEDNESDAY, Nov. 4, 2015 (HealthDay News) — Cancer cells transmitted from a common tapeworm appear to have caused cancer-like tumors in a Colombian man with HIV — the first known case of what’s called “malignant transformation,” U.S. health officials are reporting.

The parasite — known as Hymenolepis nana, or the dwarf tapeworm — is the most common human tapeworm worldwide, particularly in developing nations. At any given time, up to 75 million people carry it, according to the U.S. Centers for Disease Control and Prevention.

People can become infected with dwarf tapeworm eggs when they eat food contaminated with mouse droppings or insects, or ingest fecal matter from people carrying the parasite.

Usually, the invasion causes no symptoms, but in some people, the dwarf tapeworm can continue to reproduce itself in the intestines, according to the case report.

In the case of the man with HIV, CDC scientists suspect that his weakened immune system allowed the dwarf tapeworm to thrive unchecked. From there, mutations may have accumulated in some tapeworm cells — essentially causing cancer in the parasite — and those cells eventually caused cancer-like tumors in their human host.

That, at least, is the theory, according to Dr. Atis Muehlenbachs, one of the CDC researchers who reported on the case in the Nov. 5 New England Journal of Medicine.

“There’s still a lot we’d like to learn,” Muehlenbachs said.

The story began back in 2013, when doctors in Colombia asked the CDC for help with a puzzling case.

A 41-year-old man with HIV had come to them suffering from fatigue, weight loss, fever and coughing. CT scans revealed growths in his lungs, liver and adrenal glands.

But biopsies from the man’s lung tumors showed something bizarre: The tumors were cancer-like, but the cells were tiny.

“They were way too small to be human,” Muehlenbachs said. “They were actually about 10 times smaller than a human cancer cell.”

The tumor cells also seemed to be fusing together, the researchers found — a behavior not normally seen in human cells.

Ultimately, after a nearly three-month search for the root of the man’s illness, the CDC team found dwarf-tapeworm DNA in the patient’s tumor cells. Three days later, the man was dead. The tumors didn’t directly cause his death (kidney failure did), but they did contribute to his decline, Muehlenbachs said.

It’s not clear how or why the tapeworm cells became malignant and ultimately caused tumors in their human host, Muehlenbachs noted.

“We’d also like to know how common this is,” he said. “We think it’s rare, but we don’t know how rare.”

A severely compromised immune system is probably necessary to set the stage, according to Muehlenbachs: The patient in this case had not been taking medication to suppress his HIV infection, and he had very low numbers of infection-fighting T cells.

But since both HIV and dwarf-tapeworm infection are common in the developing world, the case raises concerns, the CDC team said: Similar cases, if they do occur, could be misdiagnosed as human cancer.

A red flag, Muehlenbachs said, would be tumor cells that seem impossibly tiny.

And how should doctors treat tapeworm-derived tumors? No one knows, Muehlenbachs said, but conventional cancer treatments might work.

The case is unique in that cancerous cells appear to have been transmitted from the tapeworm itself. But researchers have long known that some chronic infections, including certain parasites, can raise the risk of human cancers.

And that’s how this case ties into a larger picture, said Dr. Len Lichtenfeld, deputy chief medical officer for the American Cancer Society (ACS), in Atlanta.

“We know that infections can cause cancer,” Lichtenfeld said. “Hepatitis B and C can lead to liver cancer, HPV (human papillomavirus) can cause cervical cancer.”

There are even some parasitic infections that have been linked to an increased risk of developing cancers of the bladder and bile ducts, according to the ACS.

Researchers don’t know the precise mechanisms behind those infection-cancer links, though.

“The elegance of the science they used in this case is impressive,” Lichtenfeld said. “The tools they used to get answers weren’t available just a few years ago.”

The achievement, according to Lichtenfeld, raises the possibility that those same tools could be used to better understand the relationship between various infections and cancer.

On a more everyday level, Muehlenbachs said, the case underscores the importance of avoiding dwarf tapeworm infection. For the typical American, he said, that means being careful about hand-washing and consuming safe water and food when traveling to countries where the parasite is widespread.

More information

The American Cancer Society has an overview on infections and cancer risk.





from Health News / Tips & Trends / Celebrity Health http://ift.tt/1GMdY17

Hormone-Like Drug Doesn’t Help Women With Alzheimer’s: Study

By Kathleen Doheny
HealthDay Reporter

WEDNESDAY, Nov. 4, 2015 (HealthDay News) — The drug raloxifene doesn’t help the declining memory and thinking skills of women who have mild to moderate dementia due to Alzheimer’s disease, a small study suggests.

“We found no effect,” said study researcher Dr. Victor Henderson, professor of health research and policy and neurology and neurological sciences at Stanford University in California.

Raloxifene is a complex drug. It acts like the female hormone estrogen in some parts of the body, while it blocks the effects of estrogen in the breasts and uterus, the study authors explained.

The researchers decided to look at the drug after another study of raloxifene, which is also used to treat the bone-thinning disease osteoporosis, found that the drug reduced the risk of healthy women developing impairments in their thinking and memory, Henderson said.

The new study, published online Nov. 4 in Neurology, included 42 women who were recruited between 2006 and 2009 from several sites across the United States. The study participants, aged 68 to 84, all had late-onset Alzheimer’s disease that was in the mild to moderate stages.

The women were randomly assigned to take raloxifene or an inactive placebo pill for a year. The researchers tested the women’s memory and other mental functions at the start of the study and every three months after that.

Test scores didn’t differ significantly between the two groups, the investigators found. The scores didn’t differ for memory and thinking skills, or how well the women could perform activities of daily living such as dressing themselves and other routines.

However, because the number of women in the study was so small, with only 21 women receiving treatment with raloxifene, “this study can’t exclude a small effect,” Henderson said.

In addition, the findings don’t rule out that other drugs similar to raloxifene might have a benefit on thinking and memory, Henderson said. Raloxifene belongs to a class of drugs known as SERMs (selective estrogen receptor modulators). “The SERMs don’t all act in the same way,” he said.

“What this study shows,” said Heather Snyder, senior director of medical and scientific operations for the Alzheimer’s Association, “is that in this population, they don’t see a big benefit” with raloxifene.

However, she added, scientists are still trying to understand the genetic and biological reasons for Alzheimer’s, including hormonal pathways.

“I think there are a lot of things we don’t understand about the underlying biology and the role of these different pathways for Alzheimer’s disease,” she said.

About 5 million Americans are living with Alzheimer’s disease, according to the Alzheimer’s Association, although not all are diagnosed. Of those, two-thirds are women, Snyder said, “but we don’t know why.”

Women’s generally longer life expectancy may be one factor, but there may also be biological and genetic reasons, Snyder said.

Some of Henderson’s co-researchers report serving as consultants or speakers for Eli Lilly, which provided the study drug, and other pharmaceutical companies. The U.S. National Institutes of Health supported the study.

More information

To learn more about Alzheimer’s disease, visit the Alzheimer’s Association.





from Health News / Tips & Trends / Celebrity Health http://ift.tt/1Spufdz

Can You Guess Which Google Hair Trend Searches Were Tops in 2015?

purple hair

Photo: Courtesy of MIMI/Instagram

mimi-logo-il6

As we inch closer to the end of 2015 (where did the time go?), pop culture and trend analysts are busy compiling their best of lists for the year. First out of the gate is Google with their report on 2015’s hottest hair searches.

Not at all surprising, bold hair colors (silver, purple, gray and blue) were widely searched, as were a multitude of braid styles (Mohawk, twist, French, box and goddess, to name a few). But here’s where it gets interesting – man buns clocked in at the third most searched hair trend spot.

Now this isn’t exactly jaw-dropping information considering a graphic design company has been having a heck of a good time photoshopping world leaders with man buns and there is, in fact, a Man Buns of Disneyland Instagram account. But it definitely does say something about the way a dude is grooming himself these days. And we like it.

Google also notes the comb-over is getting a lot of search engine attention, but not the creepy Donald Trump kind. Think Mad Men-style Don Draper action. Now that we can get behind, although it is a drastic departure from the man bun.

So what lies ahead in 2016 for our locks? Only the beauty gods know, but we’ll be waiting impatiently to find out.

This article originally appeared on MIMIchatter.com.

More from MIMI:

3 Quick Braided Hairstyles That (Almost) Anyone Can Do

Every Single Celebrity Who Has Ever Had Rainbow Hair

popsugarblack_small.jpg MIMI Chatter is an endless stream of beauty content. We bring together the must-knows and the how-tos from your favorite sites, beauty influencers, our editors, and YOU.



from Health News / Tips & Trends / Celebrity Health http://ift.tt/1WAu284

8 Pairs of Workout Leggings That Are WAY Better Than Pants

The coming end of another year (yup, it’s already November!) can only mean one thing: It’s time to hit refresh on your workout wardrobe. And leggings—whether the classic LBLs (little black leggings) or the craziest of prints—should be at the top of your must-buy list. Why? They are perfect for going from the gym to brunch, and let’s face it, the ones you bought last year (and have worn twice a week since) are really getting worn out.

Below, check out our top 8 picks, chosen for quality and style.

Hooray for ombre

Photo: courtesy of Brooks

Photo: courtesy of Brooks

Hate it when your leggings are baggy and saggy post-run? The Brooks Streaker Capri ($85; zappos.com) has a special fabric that helps it snap back to it’s original state after each wear.

Purple reign

Photo: courtesy of New Balance

Photo: courtesy of New Balance

A wide, supportive waistband on the New Balance Premium Performance Printed Tight ($85; zappos.com) will put an end to unwanted tummy jiggle. Add in the super-cute shirring along the ankles, and you’ve got a slimming and functional pair.

RELATED: Gear Guide: The Best Cold-Weather Workout Pants

Classically cool

Photo: courtesy of Vimmia

Photo: courtesy of Vimmia

You should always have at least one pair of black leggings in your fit kit, and the Vimmia X Excellence Pant ($175; shopify.com) is a great option. Yes, they’re pricey, but the fabric regulates body temperature, keeping you warm in frigid temps and cool when it heats up, so you’re set for every season.

Move without fear

Photo: courtesy of Under Armour

Photo: courtesy of Under Armour

Built with four-way stretch, the Under Armour Fly-By Printed Legging ($60; underarmour.com) moves with you—from squat to lunge to burpee—so you never feel restricted. Also handy: strategically-placed mesh panels keep you cool while you sweat.

Sun screen

Photo: courtesy of Adidas

Photo: courtesy of Adidas

Pull on the Adidas Go-to-Gear Long Tight ($55; adidas.com) for your outdoor training sessions; it offers UPF 50 protection when you’re pounding the pavement under the sun. And a green bonus: It’s made with recycled polyester.

RELATED: Gear Up for Any Weather

Peak-a-boo print

Photo: courtesy of Gap

Photo: courtesy of Gap

Pull the GapFit gFast Modern Print Leggings’ ($65; gap.com) inner drawchord to customize the fit, and then let the side-printed panel visually slim your stems. It’s business in the front, party on the side.

Gone to the birds

Photo: courtesy Mara Hoffman

Photo: courtesy Mara Hoffman

Fly away to a soothing place with the eye-catching Mara Hoffman Long Legging ($168; zappos.com). Stash your cash in the hidden waistband pocket for a green juice post savasana.

Work horse

Photo: courtesy of Puma

Photo: courtesy of Puma

Put the Puma Clash Long Tights ($55; amazon.com) through your hardest workout (aka sweatiest) with confidence; it wicks perspiration like a champ. Plus, the two-toned pattern will turn heads in all of your cardio classes.




from Health News / Tips & Trends / Celebrity Health http://ift.tt/20uRMiz

All About the Psychedelic Club Drug Being Used to Treat Depression

Photo: Getty Images

Photo: Getty Images

Ketamine, or “Special K” as its known, is a psychedelic party drug that brings on hallucinations. You’re more likely to hear about it in the context of drug abuse these days, so you might be surprised to hear that some doctors around the country are now offering ketamine off-label to help patients with severe, treatment-resistant depression.

But in fact, ketamine already has a medicinal history: it was originally FDA-approved back in the 1970s as a fast-acting general anesthetic (although it is not approved for treating depression). Here’s everything you should know about the drug’s possible new use.

Study results are promising

In 2006 scientists at the National Institute of Mental Health (NIMH) found that a single dose of intravenous ketamine led to “robust” antidepressant effects within hours. The study was encouraging given that current antidepressants (like Lexapro or Prozac) can take weeks to kick in.

What’s more, the participants in the study had what’s called treatment-resistant depression, which suggests ketamine could help people who don’t respond to the traditional medications and therapy, including electroconvulsive therapy (which is used for severe depression). Another study done in 2013 reported similar rapid results. And last year, the director of the NIMH, Tom Insel, MD, wrote on his blog that recent data suggest intravenous ketamine may be “the most important breakthrough in antidepressant treatment in decades.”

The problem? There are a ton of unanswered questions about who it might work for, and whether or not it’s safe. (Keep reading.)

RELATED: 10 Signs You Should See a Doctor for Depression

Ketamine clinics are popping up around the country

The Ketamine Advocacy Network lists 18 clinics and providers across the U.S. During a typical IV session, a patient might experience some hallucinations and perceptual distortions—but those side effects go away. The fee per treatment ranges. A clinic in Manhattan lists a cost of $525, for example, while a doctor in Watsonville, Calif., charges $1000.

In a New York Times story published last year, Dominic A. Sisti, an assistant professor of medical ethics at the University of Pennsylvania, expressed concern about clinics that are run by anesthesiologists who don’t provide psychiatric treatment; and clinics opened by psychiatrists who may not have adequate experience with ketamine.

David Feifel, MD, a psychiatry professor at the University of California, San Diego, echoed that concern to NPR: “We’ve seen ketamine clinics open up as pure business models.” Dr. Feifel, who has been administering ketamine off-label since 2010, says his fear is that a mishap at one of these clinics could delay efforts to make the drug available to more people.

How it actually works is still unclear…but there are theories

In high doses, ketamine can cause a dissociative effect that makes a person feel detached from reality, which is why it became so popular as a club drug. But researchers have yet to figure out why it’s seems to be such a potent antidepressant.

Current evidence suggests that it might have something to do with the neurotransmitter glutamate, which is important for strengthening connections between neurons (aka brain cells). A 2012 review of the research in the journal Science posited that ketamine might work by spurring a release of glutamate that re-builds the connections in the brain that have been damaged by depression.

It’s not a miracle cure

Despite the initial relief, ketamine’s effects on depressive symptoms don’t last long. Studies show the drug can work for up to two weeks. Dr. Feifel told NPR that for one of his patients, relief fades after just one day. But as he pointed out in another interview with Medscape, even a brief respite is “a big deal to someone whose entire waking existence is unrelenting misery.”

The long-term safety is TBD

“While the science is promising, ketamine is not ready for broad use in the clinic,” NIMH director Dr. Insel concluded in his blog post about the drug. He also pointed out basic questions that still need to be answered—including the best dose and the risk of repeated injections.

For now, though, the FDA has designated ketamine a “breakthrough therapy,” which means the agency will expedite its development and review. Dr. Insel is encouraged by the move: “This speaks not only to the scientific opportunity but the public health need for having a rapid antidepressant.”

But some doctors don’t want to wait until all the results are in. Dr. Feifel told the New York Times that if he didn’t administer the drug, “I’m consigning you to lose another decade until ketamine might be ready. I just don’t feel that presumptuous.”

Pharma hopes to develop a safer alternative

A number of drug companies are testing medications similar to ketamine, sans the trippy side effects. Naurex, for example, is aiming for FDA approval of an IV drug called GLYX-13, by 2019. Johnson & Johnson is working on a nasal spray that contains a derivative of ketamine. And a small Baltimore company called Cerecor has invested $33 million in a daily pill. Earlier this year, Al Jazeera America reported that Cerecor “might be the odds-on favorite to hit the market first.”

In the meantime, some people are using it despite the lack of information about the risks and benefits. Dennis Hartman, 48, a businessman from Seattle, told the New York Times that off-label ketamine saved his life: “I look at the cost of not using ketamine—for me it was certain death.”

RELATED: 13 Helpful Books About Depression




from Health News / Tips & Trends / Celebrity Health http://ift.tt/1XQfe7A

An Oregon Teenager Has The Plague. Here’s Why You Shouldn’t Freak Out

Photo: Getty Images

Photo: Getty Images

Oregon health officials have confirmed this week that a teenage girl in Crook County, Oregon, has contracted the bubonic plague. The girl most likely caught the disease from a flea bite during a hunting trip in northern Oregon and is currently recovering in an intensive care unit at a local hospital.

The bubonic plague—yes, the same disease as the “Black Death” that crippled Europe in the Middle Ages—is an infection caused by the Yersinia pestis bacteria carried by rodents like rats, squirrels, and chipmunks, according to the U.S. Centers for Disease Control and Prevention (CDC). Humans get it from being bitten by fleas, which contract it from feeding on infected rodents.

“Many people think of the plague as a disease of the past, but it’s still very much present in our environment, particularly among wildlife,” Emilio DeBess, a veterinarian in Oregon’s Public Health Division, explained in a press release. “Fortunately, plague remains a rare disease, but people need to take appropriate precautions with wildlife and their pets to keep it that way.”

RELATED: Did One Gene Mutation Launch the Black Death?

To keep yourself and your loved ones safe, the CDC recommends avoiding sick or dead rodents, rabbits and squirrels, treating your pets for fleas, and cleaning up any areas near your house where rodents could live (think brush piles or abandoned vehicles).

Once bitten by a flea carrying the bacteria, symptoms usually develop two to six days after being bitten, and include sudden fever, headache, chills, and painful, swollen lymph nodes (known as buboes). Without immediate antibiotic treatment, the infection can spread to the bloodstream (septicemic plague) or to the lungs (pneumonic plague), both of which can be fatal.

Bubonic plague can also lead to gangrene in fingers and toes. In 2012, another Oregon patient lost fingers and toes after contracting the plague from handling a mouse his pet cat had caught, according to the Associated Press.

All of this sounds scary for sure, but the good news is that in addition to being rare in the United States, most of those who do contract the virus will recover with prompt antibiotic treatment.

While the infection is serious, the overall mortality rate for the plague today is 11%, versus 66% before antibiotics were invented.

RELATED: New York City Rats Carry Fleas Known to Transmit Plague




from Health News / Tips & Trends / Celebrity Health http://ift.tt/1Migb4X

Vaccine for Deadly Respiratory Virus Shows Promise in Early Trial

By Randy Dotinga
HealthDay Reporter

WEDNESDAY, Nov. 4, 2015 (HealthDay News) — Another research team is reporting progress toward developing a vaccine to prevent respiratory syncytial virus (RSV), a common lung infection that can cause deadly complications in infants and the elderly.

Scientists think a proven vaccine could still be years away. But the new findings add to a growing list of recent advances toward routine immunizations against the disease.

“It’s impressive,” said vaccine researcher Mark Peeples, a professor of pediatrics at Ohio State University College of Medicine, who was not involved in the study. “I’m not sure it’s going to be the best possible vaccine, but it shows a good response.”

RSV causes wintertime epidemics of respiratory illness in U.S. children. According to Peeples, virtually everyone is infected by the age of 2 and is re-infected repeatedly throughout life.

In 2 percent to 5 percent of cases, however, infected infants develop breathing problems that require hospitalization, he said. “The infection gets down into the small airways and causes swelling, which shuts off the airways,” he explained.

Oxygen is a common treatment for kids, but it’s not available everywhere. An estimated 200,000 deaths occur worldwide from the disease each year, and it is the leading cause of hospitalization for children under the age of 1 in the United States, according to background information in the study.

Researchers have been trying to develop a vaccine for decades. An early version in the 1950s actually made the disease worse, possibly because it triggered harmful inflammation, Peeples said.

In the new study, the first of three phases of research required before medications can be approved in the United States, scientists tested an experimental nose-drop vaccine in 15 adults, 15 children who’d been infected by the virus and 30 infants and children who had not. Some of the kids got a placebo.

The vaccine was developed by the U.S. National Institutes of Health’s Laboratory of Infectious Diseases. It’s a genetically engineered form of the virus that’s designed to prime the immune system but not so much that it causes illness.

The findings show that the weakened virus “still elicited a very strong immune response in infants and young children. We saw this strong immune response after only a single dose of vaccine,” said study author Dr. Ruth Karron, director of the Center for Immunization Research at Johns Hopkins University Bloomberg School of Public Health, in Baltimore.

“Though this is quite a small study,” she added, “these findings are exciting and change the way in which we think about developing live RSV vaccines for children.”

The results were published in the Nov. 4 issue of Science Translational Medicine.

Phase 1 studies like this are designed to test safety, determine an effective dosage and pinpoint side effects. The kids who got the vaccine developed more runny noses, but it’s not clear if the vaccine was the cause, Karron said. She added that it’s too early to discuss the potential cost of the vaccine.

Karron said similar vaccines are now being tested in clinical trials or will be tested soon. “We hope that a live vaccine for RSV will be available sometime within the next decade,” she added.

Earlier this year, researchers in Britain reported success in protecting calves from an illness similar to RSV. And a separate team in England tested that experimental vaccine in healthy adults and reported their immune systems responded to it. Meanwhile, Novavax Co. reported in August that an experimental vaccine reduced RSV cases in seniors by as much as 60 percent.

Another avenue of research has focused on RSV vaccines for pregnant women, who might be able to pass on protection to their unborn children, Karron said. But the protection might not last long in early life, she noted.

More information

For more about respiratory syncytial virus, see the U.S. Centers for Disease Control and Prevention.





from Health News / Tips & Trends / Celebrity Health http://ift.tt/1GLUTw0

Children of Stressed Parents May Be Prone to Obesity

WEDNESDAY, Nov. 4, 2015 (HealthDay News) — Hispanic children are more likely to be obese if their parents have high levels of stress, a new study suggests.

Researchers compared obesity rates of Hispanic children in Chicago, Miami, New York City and San Diego with their parents’ levels of stress at home and at work.

The children’s obesity rates rose according to the amount of stress their parents faced — from 20 percent among kids whose parents had no stress to 34 percent among those whose parents had three or more stress factors. Stress factors included difficulties at work or in a relationship, among others.

After adjusting for other factors such as age, gender, place of birth and neighborhood, the researchers concluded that parents with three or more chronic sources of stress were twice as likely to have obese children than those with no stress.

The findings are to be presented Friday at the Obesity Society’s annual meeting in Los Angeles. Research presented at meetings is typically considered preliminary because it’s not subject to the same level of scrutiny as studies published in journals.

“Obesity and chronic stress were both prevalent among this Latino population, with more than one-quarter (28 percent) of children ages 8 to 16 with obesity, and nearly one-third (29 percent) of their parents reporting high levels of stress,” study leader Carmen Isasi said in a society news release. Isasi is an associate professor of epidemiology and population health at Albert Einstein College of Medicine in New York City.

Isasi said the study, one of the first to identify parental stress as a risk factor for child obesity among Hispanics, adds to the understanding of family influences on youngsters’ weight.

“This research should encourage clinicians and health care practitioners to consider high stress levels as a warning sign for developing obesity not only in the adult patient, but also in the patient’s entire family,” Dr. Margarita Teran-Garcia, At-Large Mexico Council member for the Obesity Society, said in the news release.

The findings suggest “that special attention should be paid to adult patients who report experiencing high stress levels in this population, and providers are encouraged to consider behavioral counseling as one measure for obesity prevention and treatments,” Teran-Garcia added.

Further research is needed to determine how parental stress increases a child’s risk of obesity, to identify preventive measures, and to examine this link in other racial/ethnic groups, the researchers said.

More information

The U.S. National Institute of Mental Health has more about stress.





from Health News / Tips & Trends / Celebrity Health http://ift.tt/1WAdRaA